

1/20

FIGURE 1

mAb	Mean Fluorescence Intensity			% Gated	
	L1.2-CCR5	PBMC	L1.2-CCR5	PBMC	
mouse IgG1	10	4	1	1	
2D7	75	29	92	36	
PA8	48	9	73	3	
PA9	79	5	96	3	
PA10	80	8	96	5	
PA11	107	8	96	10	
PA12	115	8	96	8	
PA14	81	14	96	22	

FIGURE 2

INHIBITOR COMBINATION	CONCENTRATION RATIO	ASSAY	COMBINATION INDEX	
			90% Inhibition	50% Inhibition
PA12:2D7	10:1	Entry	0.043	0.291
	2:1	Fusion	0.017	0.019
	10:1	Fusion	0.087	0.067
	50:1	Fusion	0.158	0.046
PA12:PA14	10:1	Entry	0.437	0.535
	10:1	Fusion	0.22	0.263
PA14:2D7	1:1	Entry	2.85	1.85
	1:1	Fusion	1.34	1.74
PA12:PA11	1:1	Entry	0.707	0.641
PA12:RANTES	1000:1	Fusion	0.331	0.156
	100:1	Fusion	1.6	1.37
	100:1	Fusion	0.972	0.962
PA12:CD4-IgG2	10:1	Fusion	0.3	0.31
	1:1	Fusion	0.957	0.566
	1:1	Fusion	1.127	0.302

0 2 2 2 3 5 4 5 - 0 4 6 6 0 1

FIGURE 3

Epitopes	IC ₅₀ values (μg/ml)			
	cell-cell fusion inhibition	viral entry inhibition	gp120-binding inhibition	calcium flux inhibition
PA8	Nt	-	-	-
PA9	Nt/ECL2	-	-	0.24
PA10	Nt/ECL2	-	-	0.13
PA11	Nt	25.5	-	-
PA12	Nt	10.0	-	0.33
PA14	Nt/ECL2	1.7	.024	-
2D7	ECL2	1.6	.026	1.38
				6.4 45

FIGURE 4

	1	5	10	15	20	25	30
	M D Y Q V S S P I Y D I N Y Y T S E P C Q K I N K Q I A A A R						
2D7	92 54 90 nd 83 63 82 nd 46 40 40 90 90 86 111 49 57 45 44 37 52 27 92 65						
PA8	111 63 78 nd 52 36 32 nd 4 -2- 0 -53 -2- 45 100 57 32 56 44 37 54 24 134 36						
PA9	-16 -13 0 nd 213 -19 -13 nd 10 0 -19 -62 52 29 73 36 32 36 45 30 55 -18 145 40						
PA10	-21 -14 0 nd 175 59 -22 nd 14 -8 -15 101 48 49 94 27 47 45 45 39 53 -13 133 46						
PA11	70 32 0 nd 112 80 81 nd 40 -22 -51 74 70 46 85 32 47 56 48 40 47 -22 146 44						
PA12	68 30 2 nd 76 81 51 nd 34 -12 -49 76 68 40 86 30 41 49 46 34 54 -12 93 43						
PA14	9 86 75 nd 85 88 89 nd 57 40 64 78 84 66 76 80 71 44 86 64 76 46 99 33						
Nt	90 95 100						
ECL1	H Y A A Q W D F G N T M C Q						
2D7	70 89 40 130 40 66 58 72 82 0 -74						
PA8	38 92 59 118 32 115 96 86 68 10 -39						
PA9	31 66 27 81 -16 159 138 89 57 0 -43						
PA10	67 83 36 139 -18 133 112 97 61 0 -40						
PA11	39 81 38 91 -25 78 60 94 71 10 -60						
PA12	63 67 35 91 29 77 76 79 102 25 -55						
PA14	73 79 63 83 -23 86 47 89 80 3 -77						
ECL2	170 175 180 185 190						
2D7	R S Q K E G L H Y T C S S H F P Y S Q Y Q F W K N F Q						
PA8	62 55 1 0 62 64 65 0 83 95 53 52 32 80 92 73 62 34 73 39 33 45 102						
PA9	38 40 58 31 65 43 63 26 90 100 51 41 46 90 69 74 59 38 95 33 40 27 62						
PA10	39 28 63 15 34 -13 0 29 93 112 27 43 27 79 63 75 74 -13 51 38 12 35 39						
PA11	45 59 34 19 30 -21 0 25 84 96 32 61 39 77 82 53 68 -16 39 45 -16 38 70						
PA12	67 58 55 33 49 138 130 37 78 95 60 48 38 91 99 61 54 -24 73 47 -23 50 92						
PA14	52 56 36 31 32 102 136 39 73 85 64 49 42 101 90 45 56 -23 66 37 -28 35 74						
ECL3	265 270 275						
2D7	Q E F F G L N N C S S S N R L D Q						
PA8	63 35 29 77 61 60 71 71 78 68 77 156						
PA9	78 25 9 37 43 42 85 71 73 86 99 98						
PA10	52 22 1 67 40 50 71 81 77 90 93 112						
PA11	41 25 4 64 60 56 93 103 49 74 72 128						
PA12	60 28 10 95 60 49 78 72 70 72 75 166						
PA14	60 28 1 54 36 46 83 72 99 82 78 131						
	92 82 42 80 31 92 106 90 98 74 78 112						

76%-100+%

51%-75%

26%-50%

0%-25%

nd




FIGURE 5A

FIGURE 5B





FIGURE 6A


FIGURE 6B

FIGURE 6C




FIGURE 6D




FIGURE 7




FIGURE 8

T cell proliferation




FIGURE 9

Percent Inhibition	Combination Index			
	CD4-IgG2:T-20 Mass Ratio			
	25:1 (low)	25:1 (high)	5:1	1:1
95	0.32	0.20	0.22	0.50
90	0.38	0.25	0.27	0.55
85	0.43	0.29	0.30	0.59
80	0.47	0.33	0.34	0.62
75	0.51	0.36	0.37	0.65
70	0.54	0.39	0.40	0.67
65	0.58	0.42	0.43	0.70
60	0.61	0.45	0.45	0.73
55	0.65	0.48	0.49	0.75
50	0.69	0.51	0.52	0.78

FIGURE 10

14/20

Percent Inhibition	T-20			CD4-IgG2		
	Concentration, $\mu\text{g/ml}$	Dose Reduction	Alone	Concentration, $\mu\text{g/ml}$	Dose Reduction	Alone
99	1.1	0.17	6.6	130	4.3	29
95	0.21	0.044	4.9	19	1.10	17
90	0.10	0.024	4.2	7.8	0.59	13
70	0.025	0.0076	3.3	1.6	0.19	8.4
50	0.011	0.0039	2.8	0.60	0.095	6.3

FIGURE 11A

Percent Inhibition	Combination Index	PRO 542			PA12			T-20		
		Concentration, nM		Dose Reduction	Concentration, nM		Dose Reduction	Concentration, nM		Dose Reduction
		Alone	Mix	Alone	Mix	Alone	Mix	Alone	Mix	Alone
95	0.41	10	2.1	4.8	730	2.8	260	94	19	4.9
90	0.45	7.0	1.6	4.4	320	2.1	150	63	14	4.5
70	0.47	4.1	0.92	4.5	72	1.2	60	30	8.1	3.7
50	0.48	3.1	0.66	4.7	28	0.87	32	19	5.8	3.3

PRO 542, PA12 and T-20 were used in an approximate 1:1:10 molar concentration ratio.

FIGURE 11B

Percent Inhibition	Combination Index	PRO 542			PRO 140			T-20		
		Concentration, nM		Dose Reduction	Concentration, nM		Dose Reduction	Concentration, nM		Dose Reduction
		Alone	Mix		Alone	Mix		Alone	Mix	
95	0.40	8.5	1.9	4.5	19	1.0	19	140	17	8.2
90	0.39	7.1	1.5	4.7	13	0.77	17	100	13	7.7
70	0.37	5.3	0.87	6.1	7.2	0.46	16	57	7.7	7.4
50	0.35	4.6	0.63	7.3	4.9	0.34	14	40	5.6	7.1

PRO 542, PRO 140 and T-20 were used in an approximate 2:1:20 molar concentration ratio.

FIGURE 11C

Percent Inhibition	Combination Index	PRO 542			PRO 140			T-20		
		Concentration, nM		Dose Reduction	Concentration, nM		Dose Reduction	Concentration, nM		Dose Reduction
		Alone	Mix	Alone	Mix	Alone	Mix	Alone	Mix	Alone
95	0.24	61	2.5	24	11.9	0.72	17	156	22	7.1
90	0.22	32	1.4	23	8.4	0.40	21	96	13	7.4
70	0.19	9.8	0.50	20	4.5	0.14	32	40	4.5	8.9
50	0.18	4.7	0.26	18	3.0	0.074	41	23	2.3	10

PRO 542, PRO 140 and T-20 were used in an approximate 4:1:30 molar concentration ratio.

FIGURE 11D


18/20

Percent Inhibition	Combination Index	PRO 140			T-20		
		Concentration, nM	Dose Reduction	Concentration, nM	Dose Reduction		
Alone	Mix	Alone	Mix	Alone	Mix		
95	0.56	12	1.8	6.7	156	55	2.8
90	0.55	8.4	1.1	7.4	96	35	2.7
70	0.55	4.5	0.51	8.8	40	16	2.5
50	0.56	3.0	0.31	9.9	23	10	2.4

PRO 140 and T-20 were used in an approximate 1:30 molar concentration ratio.

Triple Combination Synergistically Blocks HIV-1 Entry (I)

19/20



20/20

FIGURE 13: *Effect of PA14 and control IgG*

